Background:
- The TEM8 receptor (ANTXR1) is overexpressed in malignant tissues, with novel oncolytic viruses such as SVV-001 uniquely binding on tumor-associated angiogenic endothelial cells, pericytes, fibroblasts, and immune inflammatory cells
- Recent pre-clinical data suggest that TEM8-targeting therapies may convert immunologically “cold” tumor microenvironments (TMEs) into “hot” milieu more amenable to treatment with immune checkpoint inhibitors (ICIs)